Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Sun Yat-sen University
- Intervention
- Orelabrutinib Oral Tablet(drug)
- Enrollment
- 39 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (11)
- Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,, Guangzhou, China, China
- Gansu Cancer Hospital, Lanzhou, Gansu, China
- Dongguan People's Hospital, Dongguan, Guangdong, China
- Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
- First People's Hospital of Guangzhou, Guangzhou, Guangdong, China
- Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
- Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
- First Affiliated Hospital of Shantou University Medical College., Shantou, Guangdong, China
- Shenzhen People's Hospital, Shenzhen, Guangdong, China
- Zhaoqing First People's Hospital, Zhaoqing, Guangdong, China
- Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
Collaborators
Fifth Affiliated Hospital, Sun Yat-Sen University · Gansu Cancer Hospital · First Affiliated Hospital of Shantou University Medical College · Southern Medical University, China · Guangdong Provincial Hospital of Traditional Chinese Medicine · Second Affiliated Hospital of Guangzhou Medical University · Fifth Affiliated Hospital of Guangzhou Medical University · Shenzhen People's Hospital · Guangzhou First People's Hospital · Dongguan People's Hospital · The First People's Hospital of Zhaoqing
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06647940 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.